ASTRAZENECA PLC Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-01-12: Form 6-K; Period of report 2018-01-12; Description FDA APPROVES LYNPARZA FOR METASTATIC BREAST CANCER; Document a7899b.htm.
- 2018-01-10: Form 6-K; Period of report 2018-01-10; Description ASTRAZENECA'S FASENRA APPROVED IN THE EU; Document a5208b.htm.
- 2018-01-02: Form 6-K; Period of report 2018-01-02; Description TOTAL VOTING RIGHTS; Document a7361a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2018-01-12 | 6-K | 2018-01-12 | FDA APPROVES LYNPARZA FOR METASTATIC BREAST CANCER | a7899b.htm |
| 2018-01-10 | 6-K | 2018-01-10 | ASTRAZENECA'S FASENRA APPROVED IN THE EU | a5208b.htm |
| 2018-01-02 | 6-K | 2018-01-02 | TOTAL VOTING RIGHTS | a7361a.htm |